Product Information
OXAZEPAM 30 MG CAPSULE is a generic product labeled by Leading Pharma, LLC, priced at $1.3494 per EA under NDC 69315091301. Its NADAC has been published 58 times since Aug 27, 2025.
FDA first approved this application on Mar 3, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Leading Pharma, LLCNDC
69315091301
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA218261FDA Approved
3/3/2025
TE Code
AB
On Market Since
7/9/2025
Pharmacological Classes
Price Statistics
The NADAC for OXAZEPAM 30 MG CAPSULE has been published 58 times since Aug 27, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3494 per EA |
|---|---|
| All-time high | $1.3640 (Sep 10, 2025) |
| All-time low | $1.1218 (May 20, 2026) |
| 52-week high | $1.3494 |
| 52-week low | $1.1218 |
| Median price | $1.2342 |
| Average price | $1.2316 |
| Largest weekly change | +9.3% (Sep 23, 2026) |
| Weeks tracked | 58 |
| Tracking since | Aug 27, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXAZEPAM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Leading Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXAZEPAM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXAZEPAM 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for OXAZEPAM 30 MG CAPSULE, manufactured by Leading Pharma, LLC, is $1.3494 per EA (NDC 69315091301), effective Sep 30, 2026.
How has the price of OXAZEPAM 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for OXAZEPAM 30 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 58 weekly CMS publications since Aug 27, 2025.
What are the highest and lowest recorded NADAC prices for OXAZEPAM 30 MG CAPSULE?
Since Aug 27, 2025, the NADAC for OXAZEPAM 30 MG CAPSULE has ranged from a low of $1.1218 (May 20, 2026) to a high of $1.3640 (Sep 10, 2025), with a median of $1.2342 per EA.
Are there cheaper alternatives to OXAZEPAM 30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of OXAZEPAM 30 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OXAZEPAM 30 MG CAPSULE?
OXAZEPAM 30 MG CAPSULE (NDC 69315091301) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.